Chen Minmin, Liu Mengyuan, Li Chenyan, Peng Shiqiao, Li Yiling, Xu Xiuying, Sun Mingjun, Sun Xuren
Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, China.
Department of Gastrointestinal Endoscopy, First Affiliated Hospital of China Medical University, Shenyang, China.
Front Oncol. 2022 Jun 10;12:913217. doi: 10.3389/fonc.2022.913217. eCollection 2022.
Immune checkpoint inhibitors (ICIs) have opened up a new way for tumor therapy but simultaneously led to the occurrence of immune-related adverse events. We report a case of successful treatment of PD-1 inhibitor-associated colitis with fecal microbiota transplantation (FMT). The patient was a palatal malignant melanoma who developed diarrhea and hematochezia accompanied by fever, gastrointestinal bleeding, and infection after the third treatment with PD-1 (Toripalimab). The patient received general treatment unsuccessful, corticosteroid therapy after initial success but rapid loss of response, and finally successful treatment after fecal microbiota transplantation.
免疫检查点抑制剂（ICIs）为肿瘤治疗开辟了一条新途径，但同时也导致了免疫相关不良事件的发生。我们报告了一例通过粪便微生物群移植（FMT）成功治疗PD-1抑制剂相关结肠炎的病例。该患者为腭部恶性黑色素瘤，在接受第三次PD-1（特瑞普利单抗）治疗后出现腹泻、便血，并伴有发热、胃肠道出血和感染。患者接受常规治疗未成功，初始使用皮质类固醇治疗有效，但很快失去疗效，最终经粪便微生物群移植治疗成功。
